Last reviewed · How we verify
collection of biological data
The drug, a collection of biological data, is currently marketed by Centre Hospitalier Universitaire Dijon, with a key composition patent expiring in 2028. The primary strength lies in its unique mechanism and data collection approach, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition and potential revenue erosion.
At a glance
| Generic name | collection of biological data |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- NCI COVID-19 in Cancer Patients, NCCAPS Study
- The Vanguard Study: Testing a New Way to Screen for Cancer (NA)
- Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda (PHASE2)
- National Cancer Institute "Cancer Moonshot Biobank"
- Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV) (NA)
- Impact of Clinical and Psychological Factors on Satisfaction With Treatment in Psoriatic Patients on Biological Therapy
- MIMICC Study in Patients With Colorectal Cancer (NA)
- Children and Adults With Chordoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- collection of biological data CI brief — competitive landscape report
- collection of biological data updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Dijon portfolio CI